{"product_id":"immp-vrio-analysis","title":"Immutep Limited (IMMP): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Immutep Limited (IMMP)'s market position as we dissect its core capabilities through the rigorous VRIO lens. This analysis distills whether its current assets truly deliver sustainable competitive advantage by examining their Value, Rarity, Inimitability, and Organization. Dive in now to see the definitive verdict on what makes Immutep Limited (IMMP) uniquely powerful - or potentially vulnerable - in today's landscape.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 1. Eftilagimod Alpha (efti) First-in-Class Status\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Immutep Limited (IMMP) and trying to figure out if their lead asset, Eftilagimod Alpha (efti), is a true long-term differentiator. Honestly, the recent activity suggests it is a significant asset, but the final verdict hinges on the Phase III data. The recent strategic licensing deal with Dr. Reddy's Laboratories is a huge vote of confidence, bringing in $20 million upfront and validating the asset's potential outside of the key markets Immutep is holding onto.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Novel Mechanism and Immediate Capital Injection\u003c\/h3\u003e\n\u003cp\u003eEftilagimod Alpha provides value because it is a first-in-class soluble LAG-3 protein and MHC Class II agonist. This unique mechanism offers a novel pathway in oncology that could change treatment standards. The market has already assigned tangible value to this potential; the recent deal secured an immediate, non-dilutive $20 million upfront payment for Immutep, which is material for a company with a market capitalization under A$300 million. Furthermore, the ongoing TACTI-004 Phase III trial in first-line NSCLC is a commercially significant indication, potentially becoming a multibillion-dollar asset if successful.\u003c\/p\u003e\n\u003cp\u003eKey value indicators include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst-in-class soluble LAG-3 protein mechanism.\u003c\/li\u003e\n\u003cli\u003eUpfront cash of $20 million secured in December 2025.\u003c\/li\u003e\n\u003cli\u003ePotential for up to $349.5 million in future milestones.\u003c\/li\u003e\n\u003cli\u003eStrong preliminary survival data, like the 81% 24-month overall survival rate from a Phase 1 study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: Pivotal Trial Status in a Crowded Field\u003c\/h3\u003e\n\u003cp\u003eYes, efti’s specific targeting approach is rare in the current immunotherapy landscape. Being the first to market with this mechanism is a rarity, but the true test is clinical validation. Immutep is now a Phase III company, which is rare for a firm of its size. The TACTI-004 trial is a global, 750-patient study spanning over 25 countries. Reaching the enrollment milestone for the futility analysis, which is expected around year-end 2025, shows operational rarity in execution.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Patent Protection and Retained Rights\u003c\/h3\u003e\n\u003cp\u003eThe core molecule and its specific mechanism of action are protected by composition-of-matter patents, making direct imitation defintely difficult. To be fair, competitors can try to target the same pathway, but the specific IP is a strong barrier. The structure of the Dr. Reddy's deal further solidifies this; Immutep retained global manufacturing rights and full commercial rights in the high-value markets of North America, Europe, and Japan. This strategic retention is a key advantage that competitors cannot easily replicate without infringing on IP or matching the existing partnership structure.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Focused Execution and Financial Backing\u003c\/h3\u003e\n\u003cp\u003eThe company is clearly organized around efti. This is evidenced by the commitment to the pivotal Phase III trial and the recent major licensing deal, which provides non-dilutive capital. For context, Immutep reported a net loss after tax of A$61.4 million for fiscal year 2025, with R\u0026amp;D expenses rising to A$61.41 million. Having A$129.7 million in cash as of June 30, 2025, and securing the upfront payment, means they are fully funded into late 2026 to execute this critical trial. The organization is structured to push efti through to potential filing from 2026–27.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for efti:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity or Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult (Patents\/Manufacturing Rights)\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eYes (Phase III Execution\/Deal Structure)\u003c\/td\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage (Contingent)\u003c\/td\u003e\n\u003ctd\u003eSustained Advantage, provided Phase III is positive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the binary risk of the Phase III TACTI-004 outcome. If the futility analysis, expected around the end of 2025, is negative, the value proposition collapses, regardless of the current IP strength. Still, the combination of the mechanism, the patent moat, and the recent financing shows a strong foundation for a sustained advantage if the clinical reasearch delivers.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 2. TACTI-004 Phase III Trial Momentum (NSCLC)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: This registrational trial in first-line Non-Small Cell Lung Cancer (NSCLC) targets one of the largest oncology markets, offering blockbuster potential if successful.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMarket Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Year\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetastatic NSCLC Market Size (7MM)\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003eUSD 21 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Metastatic NSCLC Market Size\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003eUSD 12 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKEYTRUDA NSCLC Segment Revenue Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected KEYTRUDA Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 31.51 Billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025E\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected KEYTRUDA Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 71.07 Billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2033\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected KEYTRUDA Market CAGR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.70%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2026–2033\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: No, many companies run Phase III trials, but its specific combination of eftilagimod alfa (efti) with KEYTRUDA and chemotherapy for the entire PD-L1 spectrum is a specific niche. The global Phase III trial will enrol approximately \u003cstrong\u003e756\u003c\/strong\u003e patients at more than \u003cstrong\u003e150\u003c\/strong\u003e clinical sites across over \u003cstrong\u003e25\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: No, the trial itself is a process, but the data generated, particularly efficacy across the entire PD-L1 spectrum, becomes proprietary knowledge. The FDA agreement on \u003cstrong\u003e30mg\u003c\/strong\u003e as the optimal biological dose for eftilagimod alfa (efti) is a de-risking step for future BLA filings.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Yes, the company is focused on bringing this trial to completion, with site openings in the United States following FDA dose agreement. The first patient was dosed in March 2025. The company reported a cash position of \u003cstrong\u003eA$146.25 million\u003c\/strong\u003e as of Q3 FY25, providing an expected cash reach to the end of \u003cstrong\u003eCY2026\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary, as the advantage hinges entirely on the readout, which is expected following a futility analysis scheduled for the \u003cstrong\u003efirst quarter of CY2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 3. Strategic Global Commercialization Partnership (Dr. Reddy's)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eUSD 20 million\u003c\/strong\u003e upfront non-dilutive capital received. \u003cstrong\u003eUSD 349.5 million\u003c\/strong\u003e in potential regulatory development and commercial milestone payments. Eligible for \u003cstrong\u003edouble-digit royalties\u003c\/strong\u003e on commercial sales in licensed territories.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eSecuring a major partner for a late-stage asset before final data readouts from TACTI-004. The deal was secured prior to full recruitment or data readouts from the pivotal TACTI-004 study.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eNo, the specific terms of this December 08, 2025 agreement are unique to Immutep Limited.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eThe deal structure was designed to preserve upside, showing strategic planning by retaining rights in North America and Europe. Immutep holds the \u003cstrong\u003eglobal manufacturing rights\u003c\/strong\u003e to the product across all markets.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRetained key pharmaceutical markets: North America, Europe, and Japan.\u003c\/li\u003e\n\u003cli\u003eLicensed territory: All countries outside North America, Europe, Japan, and Greater China.\u003c\/li\u003e\n\u003cli\u003eDr. Reddy's market value context: about \u003cstrong\u003eUS$12bn\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eTemporary, as the value is realized upon milestone achievement and sales, but the upfront cash is a current benefit. The upfront payment adds meaningful non-dilutive capital.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003ctd\u003eEquivalent (AUD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003eAUD 30.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003eUSD 349.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003eAUD 528.4 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDouble-digit\u003c\/strong\u003e percentage\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 4. LAG-3 Scientific Leadership and Platform\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep expertise in Lymphocyte Activation Gene-3 (LAG-3) biology allows for rational design of multiple assets (efti, IMP761) and combination strategies.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eeftilagimod alpha ($\\text{efti}$) is being evaluated in the pivotal TACTI-004 Phase III trial in first-line non-small cell lung cancer ($\\text{NSCLC}$), planned to include approximately \u003cstrong\u003e750\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003cli\u003eIn the AIPAC-003 trial (metastatic breast cancer, $\\text{MBC}$), the $\\mathbf{90mg}$ $\\text{efti}$ dose showed a \u003cstrong\u003e50%\u003c\/strong\u003e overall response rate ($\\text{ORR}$) and a \u003cstrong\u003e100%\u003c\/strong\u003e disease control rate ($\\text{DCR}$) in the safety lead-in ($\\text{N}=6$).\u003c\/li\u003e\n\u003cli\u003eIMP761, the world's first $\\text{LAG-3}$ agonist antibody, showed $\\mathbf{80\\%}$ inhibition of $\\text{T}$ cell infiltration in the skin at day \u003cstrong\u003e10\u003c\/strong\u003e at the $\\mathbf{0.9 mg\/kg}$ dose in a Phase $\\text{I}$ study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes, specialized, deep expertise in a specific, validated target pathway like $\\text{LAG-3}$ is rare outside of major pharma.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe $\\text{LAG-3}$ immune checkpoint molecule was discovered by Professor Frédéric Triebel, M.D., Ph.D., Immutep's Chief Scientific Officer.\u003c\/li\u003e\n\u003cli\u003eIMP761 is mechanistically distinct as a first-in-class $\\text{LAG-3}$ agonist antibody, contrasting with inhibitory $\\text{LAG-3}$ antibodies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Yes, scientific knowledge and institutional experience take years to build and are hard for a competitor to replicate quickly.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e$\\text{efti}$ $\\text{OS}$ (1L $\\text{NSCLC}$)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e32.9-month\u003c\/strong\u003e median Overall Survival ($\\text{OS}$)\u003c\/td\u003e\n\u003ctd\u003eINSIGHT-003 trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e$\\text{efti}$ $\\text{ORR}$ ($\\text{HNSCC}$)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e31.0%\u003c\/strong\u003e $\\text{ORR}$\u003c\/td\u003e\n\u003ctd\u003eTACTI-003 Phase $\\text{IIb}$ ($\\text{CPS} \\ge \\mathbf{20}$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e$\\text{efti}$ $\\text{ORR}$ ($\\text{HNSCC}$)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17.6-month\u003c\/strong\u003e median $\\text{OS}$\u003c\/td\u003e\n\u003ctd\u003eTACTI-003 Cohort $\\text{B}$ ($\\text{CPS} \u0026lt; \\mathbf{1}$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e$\\text{efti}$ $\\text{ORR}$ ($\\text{NSCLC}$)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60.8%\u003c\/strong\u003e $\\text{ORR}$\u003c\/td\u003e\n\u003ctd\u003eINSIGHT-003 ($\\text{N}=51$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e$\\text{IMP761}$ Safety\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eNo\u003c\/strong\u003e treatment-related adverse events\u003c\/td\u003e\n\u003ctd\u003ePhase $\\text{I}$ at $\\mathbf{0.9 mg\/kg}$ dose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, this expertise underpins the entire $\\text{R\\\u0026amp;D}$ strategy, from $\\text{efti}$ dosing to $\\text{IMP761}$ development.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImmutep completed an equity underwritten financing of approximately \u003cstrong\u003eA$100.2 million\u003c\/strong\u003e in June 2024.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalent, and term deposit position totaled approximately \u003cstrong\u003eA$181.8 million\u003c\/strong\u003e as at 30 June 2024, extending cash runway to the end of \u003cstrong\u003eCY2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company appointed the Centre for Human Drug Research ($\\text{CHDR}$) to conduct the Phase $\\text{I}$ trial for $\\text{IMP761}$.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as this is tacit knowledge embedded within the team.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 5. Robust and Expanding Intellectual Property Portfolio\n\u003c\/h2\u003e\n\u003cp\u003eThe intellectual property portfolio is a core asset, providing legal barriers to entry for key product candidates efti and IMP761.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eStrong IP protection underpins future revenue streams, with patent protection extending for significant periods for key assets.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Research and development and intellectual property expenses for fiscal year 2025 were A$61.41 million.\u003c\/li\u003e\n\u003cli\u003eThe United States patent for IMP761 is set to expire on 22 February 2037 (including 174 days of patent term adjustment).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eWhile patents are common, the breadth and specific granted claims across multiple jurisdictions contribute to rarity.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of June 30, 2023, Immutep owned or co-owned 13 patent families relating to efti, IMP761, IMP701, and IMP731.\u003c\/li\u003e\n\u003cli\u003eDuring FY25, Immutep was granted 17 new patents across key territories for both efti and IMP761.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Candidate\u003c\/th\u003e\n\u003cth\u003eJurisdiction\u003c\/th\u003e\n\u003cth\u003ePatent Expiry Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMP761\u003c\/td\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22 February 2037\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMP761\u003c\/td\u003e\n\u003ctd\u003eJapan\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 September 2036\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMP761\u003c\/td\u003e\n\u003ctd\u003eEurope\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 September 2036\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eGranted patents serve as legally binding barriers, although the overall competitive field is active.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of July 23, 2024, there were 24259 patents related to the LAG-3 target.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company has demonstrated active management of its IP estate through recent filings and sustained investment.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company secured 17 new patents for efti and IMP761 in FY25, which covers activity in late 2024\/early 2025.\u003c\/li\u003e\n\u003cli\u003eResearch and development and intellectual property expenses for fiscal year 2024 were A$41.55 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage is sustained by the legal enforceability of the granted patents.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 6. Favorable FDA Feedback for HNSCC (CPS \u0026lt;1)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Positive guidance from the FDA for late-stage development in Head and Neck Squamous Cell Carcinoma (HNSCC) for patients with low PD-L1 expression (CPS \u0026lt;1) addresses a high unmet need, as this patient segment represents up to 20% of 1L HNSCC patients and currently relies on chemotherapy-containing regimens.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes, receiving clear, supportive guidance from the FDA on a path to potential accelerated approval is not common, especially given the TACTI-003 data showing an Objective Response Rate (ORR) of 35.5% for eftilagimod alfa plus KEYTRUDA in this population, compared to a historical control ORR of 5.4% for anti-PD-1 monotherapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e No, this is a regulatory achievement specific to Immutep Limited's data package, which includes a median Overall Survival (OS) of 17.6 months in the 31 efficacy-evaluable patients in Cohort B of the TACTI-003 trial.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the company is positioned to evaluate next steps, including a potential registrational trial in this segment, with a cash, cash equivalent, and term deposit balance as at 31 December 2024 of approximately A$159.26 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as the advantage is contingent on successfully executing the agreed-upon future clinical trial, which could be a randomized registrational trial or a smaller single-arm study of 70 to 90 patients.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eEftilagimod Alfa + KEYTRUDA (TACTI-003 Cohort B, CPS \u0026lt;1)\u003c\/th\u003e\n\u003cth\u003eHistorical Control (Anti-PD-1 Monotherapy, CPS \u0026lt;1)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacy-Evaluable Patients (N)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A (Historical Control)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eObjective Response Rate (ORR) (RECIST 1.1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e35.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplete Response (CR) Rate (RECIST 1.1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisease Control Rate (DCR) (RECIST 1.1)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e58.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e32.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Overall Survival (OS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.6 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.9 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe FDA feedback supports development pathways including:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eA randomized registrational trial evaluating eftilagimod alfa in combination with KEYTRUDA against standard-of-care therapy.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eA smaller single-arm study (e.g., 70 – 90 patients) with safety, response rate, and duration of response as key endpoints, followed by a confirmatory randomized study.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 7. Cash Runway to End of CY2026\n\u003c\/h2\u003e\n\u003cp\u003e\nThe current financial position is quantified as follows:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Term Deposits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eA$109.85 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFrench R\u0026amp;D Tax Incentive Received\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e€2,588,954\u003c\/strong\u003e (approx. \u003cstrong\u003eA$4.57 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003ctd\u003eNovember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Projection\u003c\/td\u003e\n\u003ctd\u003eThrough the end of \u003cstrong\u003eCY2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTACTI-004 Futility Analysis Expected\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ1 CY2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nValue: Holding approximately \u003cstrong\u003eA$109.85 million\u003c\/strong\u003e in cash, cash equivalents, and term deposits as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, funds operations through the end of \u003cstrong\u003eCY2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nRarity: \n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nNo, many clinical-stage biotechs have cash.\n\u003c\/li\u003e\n\u003cli\u003e\nHaving runway past the key \u003cstrong\u003eTACTI-004\u003c\/strong\u003e futility readout expected in \u003cstrong\u003eQ1 CY2026\u003c\/strong\u003e is a significant buffer.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nImitability: \n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nNo, cash can be raised.\n\u003c\/li\u003e\n\u003cli\u003e\nThis current balance of \u003cstrong\u003eA$109.85 million\u003c\/strong\u003e is a specific, finite resource as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nOrganization: Yes, the company is managing burn rate effectively to achieve this runway, also supplemented by non-dilutive funding such as the \u003cstrong\u003e€2,588,954\u003c\/strong\u003e (approx. \u003cstrong\u003eA$4.57 million\u003c\/strong\u003e) French R\u0026amp;D incentive received in \u003cstrong\u003eNovember 2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nCompetitive Advantage: Temporary, as this runway will deplete; it buys time, it is not permanent.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 8. Diversified Pipeline with Autoimmune Asset (IMP761)\n\u003c\/h2\u003e\n\u003cp\u003eThe inclusion of IMP761 diversifies the portfolio by targeting the autoimmune segment, distinct from the oncology focus of eftilagimod alfa (efti).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh Potential\u003c\/td\u003e\n\u003ctd\u003eTargets rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, each representing \u003cstrong\u003emulti-billion dollar markets\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerately Rare\u003c\/td\u003e\n\u003ctd\u003eIMP761 is the \u003cstrong\u003efirst-in-class\u003c\/strong\u003e therapeutic \u003cstrong\u003eLAG-3 agonist antibody\u003c\/strong\u003e. The company harnesses LAG-3's \u003cstrong\u003eunique ability to stimulate or suppress\u003c\/strong\u003e the immune response.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eThe specific molecule IMP761 is proprietary; the company added \u003cstrong\u003e17 new patents\u003c\/strong\u003e for efti, \u003cstrong\u003eIMP761\u003c\/strong\u003e and LAG525 in various territories.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eActive management shown by continuing Phase I dose escalation to \u003cstrong\u003e2.5, 7 and 14 mg\/kg\u003c\/strong\u003e after observing \u003cstrong\u003e80%\u003c\/strong\u003e T cell infiltration inhibition at \u003cstrong\u003e0.9 mg\/kg\u003c\/strong\u003e. Additional data from Phase I are anticipated in the \u003cstrong\u003esecond half of CY2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained Potential\u003c\/td\u003e\n\u003ctd\u003eDiversifies risk away from the oncology asset, efti, which is in a pivotal Phase III trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial context for development activity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D and intellectual property expenses increased by \u003cstrong\u003e$19.9m\u003c\/strong\u003e for the financial year ended \u003cstrong\u003e30 June 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLoss after tax for the financial year ended \u003cstrong\u003e30 June 2025\u003c\/strong\u003e was \u003cstrong\u003e-$61.43 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet tangible asset backing per ordinary security was \u003cstrong\u003e9.3 cents\u003c\/strong\u003e as of \u003cstrong\u003e30 June 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePhase I trial details:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe first-in-human Phase I study is designed to enroll \u003cstrong\u003e49 healthy volunteers\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe study is being conducted by the Centre for Human Drug Research (CHDR) in the Netherlands.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eImmutep Limited (IMMP) - VRIO Analysis: 9. Global Manufacturing Rights Retention for efti\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Immutep Limited retains all global manufacturing rights for efti, allowing them to capture the margin on all sales, including those from the Dr. Reddy's deal (where they supply the product). This retention secures a margin on sales across markets licensed to Dr. Reddy's, which excludes North America, Europe, Japan, and Greater China.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes, retaining manufacturing rights in a major pharma deal is often conceded for upfront cash. The upfront payment received was \u003cstrong\u003eUSD 20 million\u003c\/strong\u003e (approximately \u003cstrong\u003eAUD 30.2 million\u003c\/strong\u003e).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e No, this is a contractual term specific to the licensing agreement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, the company has established a GMP manufacturing process for IMP761 and is supplying efti to Dr. Reddy's, showing operational capability. Immutep has achieved \u003cstrong\u003e2000L\u003c\/strong\u003e commercial scale production for efti, up from a prior \u003cstrong\u003e200L\u003c\/strong\u003e process.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, as this provides a long-term margin advantage on every dose sold globally.\u003c\/p\u003e\n\u003cp\u003eThe strategic collaboration terms with Dr. Reddy's, announced on December 8, 2025, are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTerm Component\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003eUSD 349.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eDouble-digit\u003c\/strong\u003e percentages on sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensed Territory\u003c\/td\u003e\n\u003ctd\u003eAll countries outside North America, Europe, Japan, Greater China\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetained Key Markets\u003c\/td\u003e\n\u003ctd\u003eNorth America, Europe, Japan\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Obligation\u003c\/td\u003e\n\u003ctd\u003eImmutep supplies product to Dr. Reddy's\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's operational readiness for supply is supported by its established manufacturing scale:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEfti commercial scale manufacturing process achieved: \u003cstrong\u003e2000L\u003c\/strong\u003e scale.\u003c\/li\u003e\n\u003cli\u003eIMP761 GMP manufacturing process established at \u003cstrong\u003e200L\u003c\/strong\u003e scale with Northway Biotech.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAs of September 30, 2025, Immutep Limited's financial position included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Fund Balance: Approximately \u003cstrong\u003eA$109.85 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents: \u003cstrong\u003eA$83.41 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShort-Term Investments (Term Deposits): \u003cstrong\u003eA$26.44 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDebt-to-Equity Ratio: \u003cstrong\u003e0.01\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516186452117,"sku":"immp-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/immp-vrio-analysis.png?v=1740184020","url":"https:\/\/dcf-model.com\/fr\/products\/immp-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}